HSBC Holdings
TBPH

HSBC Holdings’s Theravance Biopharma TBPH Stock Holding History

HSBC Holdings’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Buy
49,428
+6,224
+14% +$103K ﹤0.01% 2037
2026
Q1 		$696K Buy
43,204
+24,727
+134% +$437K ﹤0.01% 2051
2025
Q4 		$354K Sell
18,477
-30,440
-62% -$505K ﹤0.01% 2458
2025
Q3 		$719K Sell
48,917
-8,297
-15% -$105K ﹤0.01% 1931
2025
Q2 		$638K Buy
+57,214
New +$556K ﹤0.01% 2024
2024
Q3 		– Sell
-12,829
Closed -$108K – 3154
2024
Q2 		$108K Buy
+12,829
New +$116K ﹤0.01% 2716
2021
Q2 		– Sell
-10,412
Closed -$210K – 3079
2021
Q1 		$210K Sell
10,412
-1,718
-14% -$32.7K ﹤0.01% 2524
2020
Q4 		$212K Hold
12,130
– – ﹤0.01% 2784
2020
Q3 		$183K Hold
12,130
– – ﹤0.01% 2498
2020
Q2 		$254K Sell
12,130
-774
-6% -$19.9K ﹤0.01% 2216
2020
Q1 		$298K Buy
12,904
+3,759
+41% +$94.1K ﹤0.01% 2063
2019
Q4 		$240K Buy
+9,145
New +$178K ﹤0.01% 2706
2017
Q1 		– Sell
-6,914
Closed -$220K – 2558
2016
Q4 		$220K Buy
+6,914
New +$214K ﹤0.01% 2468

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

HSBC Holdings's TBPH Position: Q2 2026 in Review

HSBC Holdings increased its Theravance Biopharma (TBPH) stake by 14% in Q2 2026, buying an estimated $103K and bringing the position to 49,428 shares worth $843K. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

HSBC Holdings first reported a position in TBPH in Q4 2016 and has held it in 13 quarters since. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • HSBC Holdings held 49,428 shares of Theravance Biopharma worth $843K as of Q2 2026.
  • HSBC Holdings bought 6,224 Theravance Biopharma shares in Q2 2026, an estimated $103K.
  • Theravance Biopharma made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2037 holding.
  • HSBC Holdings first reported a position in Theravance Biopharma in Q4 2016 and has held it in 13 quarters since.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.